The significance of this study is several-fold. First, the dose used was equivalent to just one 325mg tablet. Second, aspirin essentially blocked tumor growth. Third, aspirin prevented satellite-cells from the tumor from migrating and creating metastasis. Fourth, aspirin essentially converted cancer cells back to normal ones or killed the ones that "refused" to convert. Fifth, aspirin was much effective in vivo as opposed to in vitro.
Btw, all of these effects of aspirin on cancer were described by Peat in his aspirin article on his website, written perhaps more than a decade ago.
Aspirin blocks growth of breast tumor cells and tumor-initiating cells and induces reprogramming factors of mesenchymal to epithelial transition. - PubMed - NCBI
"...The treatment group received aspirin orally at 75 mg/kg/day for 5 days per week, dissolved in 10 ml of milk (Peptamen (Nestle)) for 12 h during the dark for 15 days. The control group received only milk. The selected ASA dose was the human equivalent dose (HED) of ˂360 mg/60 kg/day human adult, the traditional low-to-moderate dose of ASA prescribed to patients for pains or other pathobiological reasons."
"...In this study, we demonstrate that ASA not only suppresses ER-positive and TNBC cell growth in vitro and in vivo by inducing apoptotic pathways, but also suppresses the growth of TICs/CSCs that are often considered residual cells, because after conventional therapy, these cells display mesenchymal and tumor-initiating landscapes and relapse.7,8,50 The growth-inhibitory effect of ASA is more pronounced in vivo as compared with tissue culture setup with unknown reasons."
Btw, all of these effects of aspirin on cancer were described by Peat in his aspirin article on his website, written perhaps more than a decade ago.
Aspirin blocks growth of breast tumor cells and tumor-initiating cells and induces reprogramming factors of mesenchymal to epithelial transition. - PubMed - NCBI
"...The treatment group received aspirin orally at 75 mg/kg/day for 5 days per week, dissolved in 10 ml of milk (Peptamen (Nestle)) for 12 h during the dark for 15 days. The control group received only milk. The selected ASA dose was the human equivalent dose (HED) of ˂360 mg/60 kg/day human adult, the traditional low-to-moderate dose of ASA prescribed to patients for pains or other pathobiological reasons."
"...In this study, we demonstrate that ASA not only suppresses ER-positive and TNBC cell growth in vitro and in vivo by inducing apoptotic pathways, but also suppresses the growth of TICs/CSCs that are often considered residual cells, because after conventional therapy, these cells display mesenchymal and tumor-initiating landscapes and relapse.7,8,50 The growth-inhibitory effect of ASA is more pronounced in vivo as compared with tissue culture setup with unknown reasons."
Last edited:
